October 14, 2019
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has just obtained approval for its Mont-Blanc MIS line from the Japanese authorities, authorizing it to sell these products for minimally invasive surgeries on this territory.
Spineway is now in discussions with several Japanese companies specialized in importing and distributing equipment for spinal surgery in order to choose its business partner. 
Entering the Japanese market will provide the Group with excellent prospects for development in this new high-growth country as it launches its flagship Mont-Blanc MIS product line. With a population of over 126 million, Japan represents the world’s third-largest market in value for spinal surgery and uses instruments with high added value, such as those offered by Spineway.
Spineway’s innovative Mont-Blanc MIS line, which is perfectly adapted to meet the growing needs of practitioners, has met with significant success since its launch. It is currently distributed in close to 15 countries and is already the company’s second-most popular product line.
The Group, which aims to cover the three main types of spinal disorders (degenerative, deformative and traumatological), has already made possible complex procedures (scoliosis) in minimally invasive surgeries. In the field of spinal surgery, the “minimally invasive surgery” sector is currently the most dynamic of the worldwide market and should become the technique of reference in this field in the long term.
Buoyed by this new approval and as per its NEWWAY 2021 strategic plan, Spineway continues to deploy its high added-value product lines in order to become a key international player in minimally invasive surgeries thanks to its premium product lines.
Next communication: 2019 half-year results – 29 October 2019
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 – ALSPW
Contacts:
| Spineway Shareholder-services line Available Tuesday through Thursday (10 a.m. – 12 p.m.) +33 (0)811 045 555 | Aelium Finance et Communication Investor relations Solène Kennis spineway@aelium.fr |
Attachment